Participated · Series C · Nov 2025

Ripplr operates a unified distribution network that combines logistics, on-ground execution, inventory intelligence, and retailer relationships to help consumer brands manage everything from demand forecasting to last-mile delivery. Its platform services large FMCG players such as Unilever, Nestlé, Tata, Godrej, Nivea, and Dabur. The company claims to reach roughly 100,000 retailers and to process hundreds of thousands of orders each month, underscoring its nationwide footprint and operational scale. In FY25, Ripplr’s gross revenue grew 13% year-on-year to Rs 1,164 crore, while losses remained nearly flat at Rs 91 crore. Founded by Abhishek Nehru and Santosh Dabke, the startup positions its technology backbone as a key differentiator in India’s fragmented distribution landscape. The fresh capital is expected to bolster its tech stack and expand geographic coverage, further deepening penetration with existing and new brand partners.

Participated · Series A · Jun 2025

Tacta Systems is a Palo Alto-based robotics company developing Dextrous Intelligence, a smart nervous system that gives robots human-level tactile skills and spatial awareness. Its proprietary combination of software, hardware and AI enables robots to sense, adapt, and manipulate the physical world with human-like precision and speed. The company targets industrial and consumer applications, aiming to perform delicate, variable, human-like tasks with flexibility, efficiency and autonomy. Tacta says its technology will help automate factory work and physically grueling labor. Founded by serial entrepreneurs and led by co-founder and CEO Andreas Bibl, the company announced new funding to accelerate development of its robotic solutions.

Participated · Series A · Dec 2021

VLP Therapeutics (VLPT) develops cancer treatment vaccines and prophylactic vaccines against infectious diseases such as malaria and dengue using its proprietary VLP platform. The company is advancing multiple R&D programs with the stated goal of moving into clinical trials as soon as possible. VLPT was co-founded in 2013 by Wataru Akahata, Ryuji Ueno, and Sachiko Kuno and is led by CEO Wataru Akahata. The additional capital is intended to accelerate both cancer and infectious‑disease vaccine programs and broaden R&D efforts. Financially, the company recently secured a $21M Series A-1 and previously raised $16M in a Series A in March 2021. VLP Therapeutics is a Gaithersburg, Md.–based biotech company developing a cancer treatment vaccine and prophylactic vaccines against malaria, dengue and COVID-19 using proprietary platform technologies. The company was co‑founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno and Sachiko Kuno. It focuses on research and development of vaccine candidates built on virus‑like particle (VLP) technologies. In March 2021 VLP Therapeutics completed a Series A financing totaling $16m. The company intends to use the funds to advance R&D and move its cancer treatment vaccine into clinical trials at the earliest date possible. No operating metrics were disclosed in the article.

Participated · Equity · Oct 2021

Universal Hydrogen develops an end-to-end hydrogen logistics network for aviation centered on modular hydrogen capsules that travel over existing freight networks and are handled like cargo. The company is also working to certify a powertrain conversion kit to retrofit existing regional aircraft to fly on hydrogen. Universal Hydrogen anticipates starting hydrogen deliveries for regional aircraft in 2025 and plans to expand services to larger single-aisle aircraft as auxiliary power in the late-2020s and as a primary fuel by the mid-2030s. Its approach eliminates the need for new fueling infrastructure at airports and speeds fuel loading operations. The company has assembled aviation and hydrogen industry partners and talent to build the full value chain for hydrogen aviation. No financial metrics (revenues/users) or fundraising amounts are disclosed in the article. Universal Hydrogen builds a hydrogen fuel cell powertrain and modular hydrogen fuel capsules to enable hydrogen-powered commercial flight. Its core products are lightweight, flight‑designed modular capsules for transporting green hydrogen via existing freight networks and a retrofit conversion kit to install a hydrogen‑electric powertrain on regional aircraft. The capsules are intended to deliver hydrogen directly to aircraft using existing airport cargo handling equipment without new infrastructure and are designed for flight and ground-transport safety certification. The company plans a first test flight of its fuel cell powertrain on a 40+ passenger regional airliner in 2022 and targets entry into commercial service in 2025 with certified kits for ATR 72 and De Havilland Canada Dash‑8 aircraft plus a green hydrogen fuel services offering. Universal Hydrogen reports signed LOIs from operators including Icelandair, Air Nostrum, Ravn Alaska, and ASL Aviation Holdings and says its unit economics will be equivalent or better than conventional jet-fuel variants. The company has raised $85 million in total capital to date following the new $62 million round and is headquartered in Los Angeles with an engineering center in Toulouse and a flight test center in Moses Lake, Washington. Universal Hydrogen is a Los Angeles-based startup building lightweight modular capsules to transport green hydrogen and conversion kits for aircraft fuel cells. Its capsules are designed in different sizes to serve vehicles from VTOL air taxis to long-distance single-aisle planes and to be interchangeable within each aircraft class. The company is also developing a modified 40–60-seat turboprop in collaboration with Plug Power and magniX to demonstrate regional flights of up to 700 miles. Universal Hydrogen aims to deliver an end-to-end hydrogen value chain for aviation by 2025 and ultimately to offer retrofit kits for regional airlines. The firm raised a $20.5 million Series A and will use the funds to grow its team from about 12 people to roughly 40 and accelerate technology development. The company positions its capsule logistics as a platform play to attract other producers and aircraft makers rather than being the sole aircraft manufacturer.

Participated · Equity · Oct 2019

Sensely is a London and San Francisco–based provider of a digital health and insurtech platform that uses avatar and chatbot interfaces. Its multi-lingual AI platform features a voice-enabled character interface and integrates into existing enterprise technology infrastructure. Led by Adam Odessky, CEO and co-founder, Sensely assists insurance plan members and patients with insurance services and healthcare resources. The platform is deployed with enterprise customers in the United States, United Kingdom, United Arab Emirates, Netherlands, China, Hong Kong, Japan, Switzerland, and Australia. Customers use the platform for symptom checking, insurance underwriting, claims management, medication management, and remote patient monitoring. Sensely raised $15M and intends to use the funds to accelerate commercialization efforts and extend its platform leadership. Sense.ly is a San Francisco startup that offers a virtual nurse app enabling physicians to stay in touch with patients and help prevent hospital readmissions. The app uses a nurse avatar to perform 5-minute check-ins via voice, rolling patient responses into medical records accessible to authorized providers and ingesting data from medical devices and wearables. Its platform integrates AI technologies from MindMeld, Beyond Verbal, Affectiva and others to respond to patients’ moods and provide empathetic interactions, as well as to surface mental-health signals to clinicians. Sense.ly’s core engine is rule-based and built around commonly accepted medical protocols for chronic diseases, with content and protocols added from partner hospitals and clinics. The company has focused on engaging patients aged 60 and older with conditions like COPD, heart failure and diabetes, while expanding partnerships with large providers including the U.K. National Health Service and major U.S. clinics and hospitals. CEO and founder Adam Odessky says the technology is intended to augment clinicians’ capabilities rather than replace nurses. Sense.ly provides a mobile-first virtual nurse, Molly, that engages patients via natural conversation for administrative needs and complex chronic conditions. Patients can take vitals, report on pain, sleep, stress and diet, and be connected to an attending physician via video call when risks are elevated. The platform focuses on patient engagement and remote chronic disease monitoring. Customers and partners include the National Health Service of the UK, Dudley CCG, Novartis and UCSF. Led by co-founder and CEO Adam Odessky, the company plans to use new funding to launch new markets, expand support for its global customer base, and enhance its product with artificial intelligence and machine learning. Financially, Sense.ly announced a $2.2M Series A raise to support those initiatives. Sense.ly delivers a SaaS patient-engagement platform combining advanced sensor capabilities with avatar-based technology to produce actionable, real-time data and intelligent analytics for clinicians. The platform is positioned to help clinicians monitor and engage patients while optimizing workflow. Sense.ly was co-founded by Adam Odessky (CEO) and Ivana Schnur, MD/PhD (CMO), and was incubated within Orange SA before launching independently in 2013. The company is a member of the LaunchPad Digital Health accelerator and previously graduated from the Alchemist Accelerator. Sense.ly plans to use new funding to continue building out products, expand the team, and broaden its customer base. It recently completed a seed financing round to support these initiatives.